{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:56:53Z","timestamp":1784185013037,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ctrv.2015.10.011","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T07:09:32Z","timestamp":1447139372000},"page":"41-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients"],"prefix":"10.1016","volume":"42","author":[{"given":"C.","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Palaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-8358","authenticated-orcid":false,"given":"F.","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Musella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Donfracesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vertechy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Romito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Piacenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Musio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Muzii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Tombolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Benedetti Panici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2015.10.011_b0005","unstructured":"Ovarian Cancer \u2013 National Cancer Institute. At <www.cancer.gov\/cancertopics\/types\/ovarian>."},{"issue":"4","key":"10.1016\/j.ctrv.2015.10.011_b0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2015.10.011_b0015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ygyno.2011.08.033","article-title":"Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I\/II study of the Hoosier Oncology Group","volume":"123","author":"Ramasubbaiah","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"9951","key":"10.1016\/j.ctrv.2015.10.011_b0020","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2015.10.011_b0025","first-page":"421","article-title":"Treatment of recurrent epithelial ovarian cancer","volume":"5","author":"Pisano","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"10.1016\/j.ctrv.2015.10.011_b0030","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.011_b0035","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/OTT.S40947","article-title":"Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review","volume":"7","author":"Marchetti","year":"2014","journal-title":"Onco Targets Ther"},{"issue":"19","key":"10.1016\/j.ctrv.2015.10.011_b0040","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2015.10.011_b0045","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2015.10.011_b0050","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","article-title":"Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"26","author":"Sehouli","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl. 7","key":"10.1016\/j.ctrv.2015.10.011_b0055","doi-asserted-by":"crossref","first-page":"vii218","DOI":"10.1093\/annonc\/mdq377","article-title":"Optimal treatment for relapsing ovarian cancer","volume":"21","author":"Ledermann","year":"2010","journal-title":"Ann Oncol"},{"issue":"5777","key":"10.1016\/j.ctrv.2015.10.011_b0060","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1125951","article-title":"Targeting tyrosine kinases in cancer: the second wave","volume":"312","author":"Baselga","year":"2006","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ctrv.2015.10.011_b0065","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clinbiochem.2004.05.006","article-title":"Tyrosine kinase inhibitors in cancer therapy","volume":"37","author":"Madhusudan","year":"2004","journal-title":"Clin Biochem"},{"issue":"10","key":"10.1016\/j.ctrv.2015.10.011_b0070","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/13543784.2013.816282","article-title":"Targeting tyrosine-kinases in ovarian cancer","volume":"22","author":"Morotti","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"28","key":"10.1016\/j.ctrv.2015.10.011_b0075","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.011_b0080","unstructured":"Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in platinum-resistant ovarian cancer: Hoosier Oncology Group GYN10-149. 2014 ASCO Annual Meeting. <http:\/\/meetinglibrary.asco.org\/content\/127165-144>."},{"key":"10.1016\/j.ctrv.2015.10.011_b0085","unstructured":"LUME-Ovar 1: Nintedanib (BIBF 1120) or placebo in combination with paclitaxel and carboplatin in first line treatment of ovarian cancer. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01015118>."},{"issue":"4","key":"10.1016\/j.ctrv.2015.10.011_b0090","first-page":"443","article-title":"Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma","volume":"71","author":"Keisner","year":"2011","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ctrv.2015.10.011_b0095","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.ctrv.2015.10.011_b0100","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.10.011_b0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2015.10.011_b0110","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.5068","article-title":"A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study","volume":"30","author":"Oaknin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2015.10.011_b0115","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.10.011_b0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/1471-2407-11-453","article-title":"The PACOVAR-trial: a phase I\/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer","volume":"11","author":"Eichbaum","year":"2011","journal-title":"BMC Cancer"},{"issue":"33","key":"10.1016\/j.ctrv.2015.10.011_b0125","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.011_b0130","first-page":"S5","article-title":"Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial","volume":"49","author":"Lederman","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2015.10.011_b0135","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.10.011_b0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2015.10.011_b0145","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2015.10.011_b0150","unstructured":"Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT). 2011 ASCO Annual Meeting <http:\/\/meetinglibrary.asco.org\/content\/82365-102>."},{"key":"10.1016\/j.ctrv.2015.10.011_b0155","unstructured":"<www.cancer.gov\/clinicaltrials\/search\/view?cdrid=752408&version=HealthProfessional&protocolsearchid=13663492>."},{"issue":"1","key":"10.1016\/j.ctrv.2015.10.011_b0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1586\/era.09.167","article-title":"First-line treatment of advanced ovarian cancer: current research and perspectives","volume":"10","author":"Marchetti","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"issue":"22","key":"10.1016\/j.ctrv.2015.10.011_b0165","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1158\/1078-0432.CCR-11-0411","article-title":"Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors","volume":"17","author":"Eskens","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.10.011_b0170","unstructured":"Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer. clinicaltrials.gov\/show\/NCT01853644."},{"issue":"4","key":"10.1016\/j.ctrv.2015.10.011_b0175","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-014-0078-5","article-title":"Randomized phase II trial of sorafenib alone or in combination with carboplatin\/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer","volume":"32","author":"Schwandt","year":"2014","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.ctrv.2015.10.011_b0180","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/cam4.376","article-title":"Paclitaxel\/carboplatin with or without sorafenib in the first-line treatment of patients with stage III\/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute","volume":"4","author":"Hainsworth","year":"2015","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.ctrv.2015.10.011_b0185","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/IGC.0b013e3181e273a8","article-title":"Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium","volume":"20","author":"Welch","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2015.10.011_b0190","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2011.06.019","article-title":"Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study","volume":"123","author":"Bodnar","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.10.011_b0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","article-title":"A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma","volume":"130","author":"Herzog","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2015.10.011_b0200","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/annonc\/mdq357","article-title":"A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study","volume":"22","author":"Biagi","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2015.10.011_b0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2012.07.126","article-title":"A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma","volume":"128","author":"Campos","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2015.10.011_b0210","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/annonc\/mds003","volume":"23","author":"Baumann","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2015.10.011_b0215","unstructured":"Cediranib maleate and olaparib in treating patients with recurrent ovarian, fallopian tube, or peritoneal cancer or recurrent triple-negative breast cancer. clinicaltrials.gov\/show\/NCT01116648."},{"key":"10.1016\/j.ctrv.2015.10.011_b0220","unstructured":"Cediranib maleate and olaparib or standard chemotherapy in treating patients with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer. clinicaltrials.gov\/show\/NCT02502266."},{"key":"10.1016\/j.ctrv.2015.10.011_b0225","unstructured":"Olaparib and cediranib maleate in treating patients with recurrent ovarian, peritoneal, or fallopian tube Cancer. clinicaltrials.gov\/show\/NCT02345265."},{"key":"10.1016\/j.ctrv.2015.10.011_b0230","unstructured":"Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. clinicaltrials.gov\/show\/NCT02446600."},{"key":"10.1016\/j.ctrv.2015.10.011_b0235","unstructured":"A study of cediranib and olaparib at the time ovarian cancer worsens on olaparib. clinicaltrials.gov\/show\/NCT02340611."},{"key":"10.1016\/j.ctrv.2015.10.011_b0240","unstructured":"Phase 1 and 2 study of MEDI4736 in combination with olaparib or cediranib for advanced solid tumors and recurrent ovarian cancer. clinicaltrials.gov\/show\/NCT02484404."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215001978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215001978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T04:57:04Z","timestamp":1599800224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737215001978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":48,"alternative-id":["S0305737215001978"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.011","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}